Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 12.7% in January

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 50,692 shares, a drop of 12.7% from the January 15th total of 58,049 shares. Based on an average trading volume of 70,257 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the company’s shares are sold short. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 70,257 shares, the short-interest ratio is currently 0.7 days.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. 28.40% of the stock is currently owned by institutional investors and hedge funds.

Anebulo Pharmaceuticals Stock Up 0.4%

Shares of ANEB opened at $0.48 on Wednesday. Anebulo Pharmaceuticals has a fifty-two week low of $0.44 and a fifty-two week high of $3.42. The company’s fifty day moving average is $1.17 and its two-hundred day moving average is $2.00. The firm has a market cap of $19.62 million, a PE ratio of -2.53 and a beta of -0.81.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. As a group, equities research analysts anticipate that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.